BioNTech

BioNTech

Verified
Develops personalized immunotherapies with a focus on cancer medicine

Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues---109m482m17.3b15.6b
% growth----342 %3498 %(10 %)
EBITDA---(148m)(43m)13.8b13.3b
% EBITDA margin---(136 %)(9 %)80 %85 %
Profit---(179m)15m9.2b9.1b
% profit margin---(164 %)3 %53 %58 %
R&D budget47m55m91m199m---
R&D % of revenue---183 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
N/AN/ASeed
N/ASpinout
*
€225mSeries A
*
€80m
Valuation: €2.5b
Growth Equity VC
*
$325m
Valuation: $2.5b
Series B
$55mGrant
N/A$150m
Valuation: $3.4b
IPO
$55.8mDebt
$250mPrivate Placement VC
€100mDebt
€375mGrant
*
N/A$150mPost IPO Equity
Not yet verified
Total Funding$1.4b

Recent News about BioNTech

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by BioNTech

Edit
Neon Therapeutics
ACQUISITION by BioNTech Jan 2020
PhagoMed Biopharma
ACQUISITION by BioNTech Nov 2021